transjugular intrahepatic portosystemic shunt (TIPS)
Jump to navigation
Jump to search
Introduction
Interventional radiology technique.
Indications
- useful for relieving portal pressure in patients with
- control refractory hemorrhage in candidates for liver transplantation
Clinical significance
- useful for patients who are poor surgical candidates
- success rate in control of esophageal varices is > 90%
Procedure
- angiographic placement of an expandandable metallic stent from a branch of the hepatic vein through the hepatic parenchyma into a branch of the portal vein
- rifaximin 600 mg bid starting 14 days prior to procedure & continuing for 6 months prevents hepatic encephalopathy[7]
Complications
- shunt occlusion (50% in 1 year)
- increased risk of hepatic encephalopathy 15-25% (3-5% severe)[2]
- morbidity of 20% & early mortality of 5%
Notes
- there is little evidence that TIPS improves mortality
- preemptive TIPS in patients with cirrhois & acute variceal hemorrhage improves survival[6]
- recurrence of variceal bleeding after TIPS is almost always caused by stenosis or occlusion of the shunt
More general terms
References
- ↑ Manual of Medical Therapeutics, 28th ed, Ewald & McKenzie (eds), Little, Brown & Co, Boston, 1995, pg 352
- ↑ 2.0 2.1 Journal Watch 20(3):22, 2000
- ↑ Chalasani N et al Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology 118:138, 2000 PMID: https://www.ncbi.nlm.nih.gov/pubmed/10611162
- ↑ Medical Knowledge Self Assessment Program (MKSAP) 11, 14, 17. American College of Physicians, Philadelphia 1998, 2006, 2015
- ↑ American Association for the Study of Liver Diseases. Boyer TD, Haskal ZJ The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology. 2010 Jan;51(1):306. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19902484
- ↑ 6.0 6.1 Hernandez-Gea V, Procopet B, Giraldez A et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: An observational study. Hepatology 2018 Jul 16; PMID: https://www.ncbi.nlm.nih.gov/pubmed/30014519 https://aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1002/hep.30182
- ↑ 7.0 7.1 Bureau C, Thabut D, Jezequel C et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled trial. Ann Intern Med 2021 Feb 2; PMID: https://www.ncbi.nlm.nih.gov/pubmed/33524293 https://www.acpjournals.org/doi/10.7326/M20-0202